Focal adhesion kinase (FAK) plays a key role in mediating signaling downstream of integrins and growth factor receptors. In this study, we determined the roles of FAK in vivo by generating a megakaryocyte lineage–specific FAK-null mouse (Pf4-Cre/FAK-floxed). Megakaryocyte and platelet FAK expression was ablated in Pf4-Cre/FAK-floxed mice without affecting expression of the FAK homologue PYK2, although PYK2 phosphorylation was increased in FAK−/− megakaryocytes in response to fibrinogen. Megakaryopoiesis is greatly enhanced in Pf4-Cre/FAK-floxed mice, with significant increases in megakaryocytic progenitors (CFU-MK), mature megakaryocytes, megakaryocyte ploidy, and moderate increases in resting platelet number and platelet recovery following a thrombocytopenic stress. Thrombopoietin (Tpo)–mediated activation of Lyn kinase, a negative regulator of megakaryopoiesis, is severely attenuated in FAK-null megakaryocytes compared with wild-type controls. In contrast, Tpo-mediated activation of positive megakaryopoiesis regulators such as ERK1/2 and AKT is increased in FAK-null megakaryocytes, providing a plausible explanation for the observed increases in megakaryopoiesis in these mice. In Pf4-Cre/FAK-floxed mice, rebleeding times are significantly increased, and FAK-null platelets exhibit diminished spreading on immobilized fibrinogen. These studies establish clear roles for FAK in megakaryocyte growth and platelet function, setting the stage for manipulation of this component of the Tpo signaling apparatus for therapeutic benefit.

Focal adhesion kinase (FAK) is an essential nonreceptor protein tyrosine kinase that is expressed ubiquitously and is conserved in mammals and lower eukaryotic organisms.1,,4  The principal FAK stimulus is integrin engagement (Guan and Shalloway5  and reviewed in Parsons6 ), although its direct interaction with, and activation via, platelet-derived and epidermal growth factor receptors suggests that it may also function downstream of other membrane-bound growth factor and cytokine receptors.7  Autophosphorylation of FAK Tyr397 occurs rapidly following integrin activation, and the resulting phosphorylated residue acts as a docking site for the SH2 domains of Src-family kinases.8,9  FAK catalytic activity is increased by subsequent Src-mediated phosphorylation of FAK residues Tyr576 and Tyr577,10  followed by Tyr861 and Tyr925, which act as binding sites for the SH3 domain of p130CAS and the SH2 domain of the adaptor protein GRB2, respectively.11,12  Tyr925, located in the focal adhesion targeting domain, also mediates interactions with integrin-associated proteins such as talin and paxillin,13  thereby recruiting FAK to focal adhesion sites.

Activated FAK modulates the activity of a broad range of downstream signaling proteins, including phosphoinositide 3-kinase (PI3-K)14  and phospholipase C (PLC)–γ,15  as well as a number of small GTPases such as Ras, Rac, and Rho (reviewed in16 ). Extensive studies indicate that FAK is essential for normal cell migration. FAK-deficient cells migrate poorly in response to chemokines; form an increased number of prominent “immature” focal adhesions, apparently due to decreased focal adhesion turnover; and do not spread normally on extracellular matrices (ECMs).17,18 

Megakaryopoiesis and platelet production are tightly regulated by a number of growth factors and cytokines to maintain a normal number of circulating platelets. The principal regulator of megakaryopoiesis is thrombopoietin (Tpo),19  although other factors such as interleukin-3 and stem-cell factor work in synergy with Tpo during the earlier stages of megakaryocytic progenitor cell expansion.20  It has become apparent that the microenvironments in which megakaryocytes function are also of critical importance to megakaryopoiesis.21,22  Indeed, direct cell-cell and cell-ECM interactions have been demonstrated to influence megakaryocyte differentiation and proplatelet formation.23,25  Although FAK is important in regulating cell spreading and migration in response to integrin-ECM interactions, the role of FAK in megakaryopoiesis remains unclear, partly because Fak deletion in mice is lethal at embryonic day 8.5, before the onset of significant definitive hematopoiesis. Although the role of proline-rich tyrosine kinase-2 (PYK2), which shares sequence homology and similar characteristics with FAK, has been characterized in megakaryocytes,8,26,28  its localization and dependence on intracellular calcium make the 2 proteins functionally different.29 

FAK activation in platelets requires the costimulation of integrins and agonist receptors. Platelet adhesion to fibrinogen and collagen via integrins αIIbβ3 and α2β1, respectively, leads to rapid FAK phosphorylation on tyrosine residues in a manner dependent on a platelet agonist, such as adenosine diphosphate (ADP), and on activation of protein kinase C.30,,33  FAK phosphorylation in response to costimulation with either fibrinogen or collagen and ADP accompanies changes in platelet spreading.34  Using nonplatelet models, it has been inferred that FAK may mediate platelet spreading via phosphorylation of α-actinin, which colocalizes with a number of cytoskeletal proteins, including actin, vinculin, and zyxin, and is essential for the organization of the actin cytoskeleton.35  However, any required role for FAK in platelet function remains unknown. To more fully evaluate the role of FAK in megakaryopoiesis and platelet function in vivo and in vitro, we have here successfully ablated FAK expression specifically in megakaryocytes and platelets by crossing conditional Fak-floxed36  mice with a recently described megakaryocyte lineage–specific platelet factor 4 (Pf4)–Cre mouse.37  FAK ablation leads to a dramatic increase in the number of megakaryocyte progenitor cells and mature bone marrow megakaryocytes. In addition, megakaryocyte maturation was greatly enhanced, probably as a result of altered Tpo signaling. Furthermore, Fak−/− mice exhibit increased bleeding times, and their platelets spread poorly on fibrinogen, establishing FAK as a requisite player in megakaryocyte and platelet biology.

Materials

Tissue culture plastics were purchased from Corning (New York, NY) and standard tissue culture media from Invitrogen (Carlsbad, CA). Fibrinogen was purchased from Enzyme Research Laboratories (South Bend, IN). Human plasma fibronectin, mouse monoclonal anti-FAK, rat anti–mouse monoclonal anti-αIIb (MWReg30), and rat anti–mouse monoclonal CD41-FITC antibodies were purchased from BD Biosciences (La Jolla, CA). Rabbit anti-phosphoERK1/2, rabbit anti-phosphoAKT, rabbit anti-phosphoPYK2, rabbit anti-phosphoFAK, rabbit anti-PYK2, and rabbit anti-FAK antibodies were purchased from Cell Signaling Technology (Danvers, MA). Rabbit anti–mouse von Willebrand factor (VWF) antibody was purchased from Abcam (Cambridge, MA). Goat anti–rabbit horseradish peroxidase (HRP) and rabbit anti–mouse HRP were from Santa Cruz Biotechnology (Santa Cruz, CA). ECL-plus chemiluminescent reagent was purchased from GE Lifesciences (Piscataway, NJ). Recombinant human Tpo was a gift from Don Foster, Zymogenetics (Seattle, WA).

Animals

Wild-type (WT), Pf4-Cre, and Fak-floxed mice were all previously bred onto a C57Bl/6 genetic background and were generated as previously described.36,37  Mice were routinely genotyped from tail DNA by polymerase chain reaction (PCR) using primers specific for the Pf4 promoter (CCCATACAGCACACCTTTTG) and Cre-cDNA (TGCACAGTCAGCAGGTT), which amplified a 450–base pair (bp) product. Mice also were condition Fak-floxed (forward: GAATGCTACAGGAACCAAATA and reverse: GAGAATCCAGCTTTGGCTGTT), which amplified a 290-bp WT product and 400-bp Fak-floxed product. Mice were housed in a pathogen-free environment and the Animal Care Program of the University of California San Diego approved all protocols. For all experiments, 6- to 12-week-old mice were used.

Preparation of megakaryocytes and platelets

Megakaryocytes were expanded and separated as previously described.38  Briefly, flushed bone marrow was cultured in serum-free medium containing 3% Tpo supernatant (previously prepared and quantified from a mouse Tpo-secreting baby hamster kidney [BHK] cell line) for 72 hours. Mature megakaryocytes were isolated by passing the culture through a discontinuous bovine serum albumin (BSA) density gradient. For hematopoietic colony assays, fresh bone marrow was cultured according to the manufacturer's protocol (MegaCult and MethoCult; Stem Cell Technologies, Vancouver, BC). Megakaryocyte colonies were stained and scored after 7 days and other colonies scored after 10 days in culture. For platelet preparation, mice were anesthetized with pentobarbitol (1 mg/10 g body weight; Ovation Pharmaceuticals, Deerfield, IL) and blood was drawn from the hepatic portal vein in heparin (15 U/mL blood). Blood was diluted with one volume of wash buffer (150 mM NaCl, 20 mM HEPES [N-2-hydroxyethylpiperazine-N′-2-ethanesulfonic acid]; pH 6.5) and centrifuged at 60g for 7 minutes. Platelet-rich plasma (PRP) was centrifuged at 240g for 10 minutes and platelets resuspended in Walsh buffer (137 mM NaCl, 20 mM HEPES, 5.6 mM dextrose, 1 g/L BSA, 1 mM MgCl2, 2.7 mM KCl, 3.3 mM NaH2PO4; pH 7.4). Tpo-dependent UT7/Tpo cells were routinely cultured in Iscoves modified Dulbecco medium (IMDM; Invitrogen) containing 10% fetal bovine serum (FBS) and 10ng/mL human recombinant Tpo. For Tpo-stimulation experiments, cells were serum and Tpo starved for 18 hours before the addition of Tpo.

Platelet recovery and plasma Tpo quantification

Complete blood counts were routinely taken following retro-orbital blood samplings. To study platelet recovery, baseline platelet counts were obtained from Pf4-Cre/FAK-floxed mice and age-matched controls. Seven days later, mice were given anti–mouse CD41 antibody (0.5 μg/g body weight) via intraperitoneal injection, and platelet counts were obtained at 24, 40, 90, and 170 hours after injection.39  Plasma Tpo concentration was quantified by enzyme-linked immunosorbent assay (ELISA), according to the manufacturers' protocol (Quantikine; R&D Systems, Minneapolis, MN).

Western blot analyses

Megakaryocytes and platelets were lysed in NP-40 lysis buffer (50 mM Tris [tris(hydroxymethyl)aminomethane]–HCl, pH 7.4, 1% NP-40, 150 mM NaCl, 1 mM EDTA [ethylenediaminetetraacetic acid], 1 mM Na3VO4, 1 mM NaF) containing 1% protease inhibitors (Sigma, St Louis, MO). Mouse tissue samples were collected and solubilized in standard radio-immunoprecipitation assay (RIPA) buffer for 15 minutes at 4°C and ground using a Micropestle (Eppendorf, Westbury, NY). After protein samples were cleared by centrifugation at 15 000g for 15 minutes, the supernatant was collected. Denatured proteins were fractionated by SDS–polyacrylamide gel electrophoresis and transferred to polyvinylidene difluoride (PVDF) membrane. Protein expression was detected by incubating with specific antibodies and visualized by chemiluminescent detection reagent.

Lyn kinase assay

Megakaryocytes were serum and Tpo starved overnight before being stimulated with 50ng/mL rhTpo for 10 minutes and lysed in NP-40 lysis buffer. Lyn protein was immunoprecipitated from 500μg of whole-cell lysate using a rabbit anti-Lyn antibody (Cell Signaling Technologies) overnight at 4°C. Protein A/G-plus agarose beads (Santa Cruz Biotechnology) were added and lysates were incubated for a further 2 hours at 4°C. Beads were washed once in standard RIPA buffer and 3 times in kinase buffer (60 mM HEPES, 10 mM MgCl2, 5 mM MnCl2, 300 μM Na3VO4, 1.25 mM dithiothreitol [DTT]) and resuspended in 35 μL kinase buffer containing 320 ng of cdc2(Tyr15)-biotinylated peptide (Cell Signaling Technologies), 20 μM adenosine triphosphate (ATP), and 10 μCi (370 kBq) [γ-32P]-ATP. Mixtures were incubated with agitation for 15 minutes at room temperature before the reaction was stopped by adding 50 μL of 100 mM EDTA. Thirty microliters of reaction mixture was then spotted onto SAM2  biotin capture membrane (Promega, Madison, WI) and the membrane washed 3 times in 2 M NaCl and 4 times in 2 M NaCl, 1% H3PO4. The membrane was dried and exposed to autoradiography film before absorbed radioactivity was quantified using a scintillation counter (LS500; Beckman Coulter, Fullerton, CA).

Ploidy analysis

For ploidy analyses, red cell–depleted bone marrow was stained with anti–CD41-FITC, then fixed and permeabilized in cold 30% ethanol for 12 hours. DNA was stained by adding 10 μg/mL propidium iodide (Sigma) and incubating for 1 hour. Analyses were performed using a FACScaliber flow cytometer (BD Biosciences). DNA plots were taken from large CD41 high-expressing cells only. On average, large CD41 high-expressing cells represented approximately 0.5% of the total bone marrow population.

Cell-spreading assays

Sterile coverslips were coated with 100 μg/mL fibrinogen in phosphate-buffered saline (PBS; pH 8.0) overnight and blocked for 2 hours in PBS containing 1% BSA. Platelets were resuspended in Tyrode buffer (150 mM NaCl, 2.5 mM KCl, 12 mM NaHCO3, 2 mM MgCl2, 2 mM CaCl2, 1 mg/mL BSA, 1 mg/mL dextrose, pH 7.4) at 107 platelets/mL. Cells were incubated on fibrinogen for 1 hour at 37°C in the presence or absence of specific agonists. Nonadhered cells were removed by washing with PBS before adhered cells were fixed with 4% PFA for 10 minutes at room temperature and permeabilized with PBS, 0.1% Triton X-100. Following antibody staining, platelet samples were mounted in Citifluor mounting medium (Ted Pella, Redding, CA) and visualized using a Nikon Eclipse TE2000-U microscope (Nikon, Melville, NY) with a 60× A/1.4 oil objective (f/0.17 WD 0.21). Images were captured using Photometric Cool Snap HQ camera (Photometrics, Tucson, AZ) and QED InVivo version 2.0 imaging software (Media Cybernetics, Silver Spring, MD). Images were processed using Photoshop 5.5 software (Adobe, San Jose, CA). Quantification of spreading was performed blindly using ImageJ software (http://rsb.info.nih.gov/ij/) with platelet surface area measured in pixels. An average of 800 platelets per data point were enumerated from 6 mice of each genotype.

For cytospin preparations, megakaryocytes were resuspended at 104 cells per milliliter and cytospun onto a Superfrost/Plus microscope slide (Fisher Scientific, Pittsburgh, PA) using a Cytospin 4 cytocentrifuge (Thermo Shandon, Pittsburgh, PA). Platelet fibrinogen–binding assays and clot-retraction assays were performed as previously described.40 

Immunofluorescence microscopy

Platelets were allowed to adhere to fibrinogen-coated coverslips as described in “Cell-spreading assays.” Nonspecific antibody binding was blocked using 10% rabbit or goat serum in PBS before primary antibody incubations. Primary antibodies were used at 1:400 dilutions (vinculin and β3 integrin) in 10% serum PBS and incubated for 45 minutes at 37°C. Secondary antibodies (goat polyclonal anti-β3 integrin-Alexa-Fluor488 and mouse monoclonal anti-vinculin Alexa-Fluor594 antibodies; Invitrogen) were incubated at 1:400 dilutions for 30 minutes at room temperature. Following antibody staining, platelet samples were mounted in Citifluor mounting medium and visualized using a Nikon Eclipse TE2000-U microscope with a 60× A/1.4 oil objective (f/0.17 WD 0.21). Images were captured using the Photometric Cool Snap HQ camera and QED InVivo imaging software. Images were processed using Photoshop version 5.5 software. Megakaryocyte cytospins were mounted in Vectorshield (Vector Laboratories, Burlingame, CA) and visualized using a Leica DMLS upright microscope (Leica Microsystems, Wetzlar, Germany) with a 40× N-plan ∞/0.17/D objective. Images were captured using a Diagnostic SPOT camera and SPOT-advanced software (Diagnostic Instruments, Sterling Heights, MI), and imported into Corel Photo-Paint 11 (Corel, Ottawa, ON).

Immunohistochemistry

Femurs from Pf4-Cre/FAK-floxed and age-matched control mice were fixed in 4% PFA for 24 hours and decalcified in 5% EDTA for 48 hours. Paraffin sections (5-μm thickness) were deparaffinized and antigen retrieval was performed in EDTA buffer (pH8) at 95°C for 30 minutes. All solutions were made in Tris-buffered saline (TBS) plus or minus 0.1% Tween-20 (TBS-T) and slides washed in 3 changes of TBS-T for 3 minutes each time, unless otherwise stated. Endogenous peroxidase activity was inhibited with 0.6% H2O2, and nonspecific binding was blocked using 10% goat serum. Sections were incubated with rabbit anti-VWF primary antibody (1:300 dilution) for 2 hours at 37°C followed by a goat anti-rabbit biotinylated secondary antibody (1:300 dilution; Vector Laboratories) for 30 minutes at room temperature. Positive staining was detected using streptavidin reagent (avidin-biotin complex [ABC]; Vector Laboratories) and diaminobenzidine tetrahydrochloride (DAB; Vector Laboratories) before samples were counterstained using Harris hematoxylin (Fisher Scientific) mounted in Clarion mounting medium (Sigma) and visualized using a Leica DMLS upright microscope with a 40× N-plan ∞/0.17/D objective. Images were captured using a Diagnostic SPOT camera and SPOT-advanced software and imported into Corel Photo-Paint 11. For quantitative analysis of positively stained megakaryocytes in the bone marrow, 25 images (×200 magnification) were taken of either Pf4-Cre/FAK-floxed or WT marrow. Megakaryocyte enumeration was performed blindly.

Tail rebleeding

Tail bleeding assays were performed as previously described.41  Briefly, the distal 3 mm of the tail tip from age- and sex-matched Pf4-Cre/FAK-floxed and WT mice were dissected with a sharp scalpel. After cutting, the mice were placed back in cages and clotting was allowed to progress for approximately 10 minutes. Tails were then immersed in a saline solution kept at 37°C to restart bleeding. Rebleeding time was measured as the time taken for the stream of blood from the tail tip to stop. If rebleeding time for any mouse had exceeded 120 seconds, that mouse would have been removed from the experiment.

Specific ablation of Fak expression from the megakaryocyte lineage in Pf4-Cre/FAK-floxed mice

To determine the roles of FAK in megakaryocytes and platelets, we generated a megakaryocyte lineage–specific FAK knockout mouse. FAK protein expression, determined by Western blot, was completely ablated in mature bone marrow–derived megakaryocytes and in washed platelets from Pf4-Cre/FAK-floxed mice, in contrast to WT controls (Figure 1A). Expression levels of the FAK homologue PYK2 in megakaryocytes and in platelets from Pf4-Cre/FAK-floxed mice were comparable to those in WT controls. Immunofluorescence microscopy on cytospin preparations confirmed the absence of FAK expression in mature megakaryocytes derived from Pf4-Cre/FAK-floxed bone marrow (Figure 1B). Although expression levels of PYK2 were comparable, we tested whether PYK2 activation in megakaryocytes and in platelets derived from Pf4-Cre/FAK-floxed was different from that of WT mice. Megakaryocytes were exposed to either BSA or fibrinogen-coated tissue culture plastics and stimulated with 1 mM MnCl2 for 15 minutes. Adhesion to fibrinogen stimulated a greater increase in tyrosine phosphorylation of PYK2 in Fak−/− megakaryocytes compared with WT megakaryocytes (Figure 1C). However, Fak−/− platelets and WT platelets showed similar increases in tyrosine phosphorylation of PYK2 in response to ADP (Figure 1D), a PAR4 receptor activating peptide or MnCl2-induced fibrinogen binding (data not shown). Western blots were performed on lysates taken from multiple tissues to determine whether ablation of FAK expression was restricted to the megakaryocyte lineage. FAK expression was comparable to WT in Pf4-Cre/FAK-floxed heart, lung, liver, and spleen lysates (Figure 1E).

Figure 1

FAK ablation in megakaryocytes and platelets. (A) Bone marrow–derived megakaryocytes and freshly isolated platelets were lysed and FAK and PYK2 protein expression determined by Western blotting. (B) Cytospin preparations of mature bone marrow–derived megakaryocytes are shown, stained for FAK expression (green) and DNA (blue). The staining shown is representative of approximately 50 cells in each group. Relevant immunoglobulin controls are shown as insets. (C) Western blot analyses of phospho-PYK2 in response to fibrinogen and MnCl2 in megakaryocytes and (D) in platelets in response to ADP derived from Pf4-Cre/FAK-floxed and WT mice. (E) Western blot analyses of FAK protein expression by nonmegakaryocytic tissues in Pf4-Cre/FAK-floxed and WT mice.

Figure 1

FAK ablation in megakaryocytes and platelets. (A) Bone marrow–derived megakaryocytes and freshly isolated platelets were lysed and FAK and PYK2 protein expression determined by Western blotting. (B) Cytospin preparations of mature bone marrow–derived megakaryocytes are shown, stained for FAK expression (green) and DNA (blue). The staining shown is representative of approximately 50 cells in each group. Relevant immunoglobulin controls are shown as insets. (C) Western blot analyses of phospho-PYK2 in response to fibrinogen and MnCl2 in megakaryocytes and (D) in platelets in response to ADP derived from Pf4-Cre/FAK-floxed and WT mice. (E) Western blot analyses of FAK protein expression by nonmegakaryocytic tissues in Pf4-Cre/FAK-floxed and WT mice.

Close modal

Increased megakaryocyte progenitor number in Pf4-Cre/FAK-floxed mice

Complete blood counts demonstrated no differences in measured blood lineages, apart from a moderate but significant increase in platelet numbers in Pf4-Cre/FAK-floxed mice (Table 1; 704 × 103/μL ± 16.9 in WT compared with 836 × 103/μL ± 28.7 in Fak−/− mice; P = .041).

Table 1

Complete blood counts of WT and Pf4-Cre/FAK-floxed (Fak−/−) mice

Test parameterWT miceFak−/− Mice
WBC, × 103 8.88 (± 0.78) 9.53 (± 0.69) 
RBC, × 106 8.84 (± 0.13) 8.89 (± 0.19) 
PCV, % 42.0 (± 1.01) 41.1 (± 0.78) 
PLTs. × 103 704 (± 16.9) 836 (± 28.7)* 
MPV, μ3 4.67 (± 0.06) 4.72 (± 0.05) 
Test parameterWT miceFak−/− Mice
WBC, × 103 8.88 (± 0.78) 9.53 (± 0.69) 
RBC, × 106 8.84 (± 0.13) 8.89 (± 0.19) 
PCV, % 42.0 (± 1.01) 41.1 (± 0.78) 
PLTs. × 103 704 (± 16.9) 836 (± 28.7)* 
MPV, μ3 4.67 (± 0.06) 4.72 (± 0.05) 

Values are means (± SEM) of 9 mice in each group.

WBC indicates white blood cells; RBC, red blood cells; PCV, packed cell volume; PLTs, platelets; and MPV, mean platelet volume.

*

P < .05.

Based on the increase in platelets, several assays were performed to determine whether the absence of FAK has a direct effect on megakaryopoiesis or thrombopoiesis. The number of megakaryocyte colony-forming units (CFU-MK) in Pf4-Cre/FAK-floxed mice was determined using standard semisolid collagen-based colony assays with increasing concentrations of Tpo to support megakaryocyte lineage growth. CFU-MK number was increased nearly 4-fold in Pf4-Cre/FAK-floxed mice compared with WT at 0.5ng/mL Tpo (Figure 2A; 2.67 ± 0.22 colonies per 2 × 104 bone marrow cells in WT mice vs 10.67 ± 1.04 colonies per 2 × 104 bone marrow cells in Pf4-Cre/FAK-floxed mice). At higher Tpo concentrations (5 and 50 ng/mL), CFU-MK number was approximately 2-fold greater in Pf4-Cre/FAK-floxed mice than in WT mice. Fifty ng/mL of Tpo resulted in growth of WT CFU-MK colonies, and no colonies were observed in the absence of Tpo (data not shown). In contrast to the results for CFU-MK, the numbers of other hematopoietic colonies (CFU-G/M, BFU-E and CFU-E) were comparable in WT and Pf4-Cre/FAK-floxed mice (Figure 2B).

Figure 2

Increased megakaryocyte progenitor numbers in Pf4-Cre/FAK-floxed mice. (A) Colony assays for CFU-MK demonstrate a significant increase in the number of colonies from Pf4-Cre/FAK-floxed mice compared with controls. The results shown are the mean (±SEM) of 3 independent experiments. ***P < .01. (B) Colony assays for CFU-G/M, BFU-E, and CFU-E from Pf4-Cre/FAK-floxed and WT mice. No significant differences were found between the groups. The results represent the mean (± SEM) of 3 independent experiments.

Figure 2

Increased megakaryocyte progenitor numbers in Pf4-Cre/FAK-floxed mice. (A) Colony assays for CFU-MK demonstrate a significant increase in the number of colonies from Pf4-Cre/FAK-floxed mice compared with controls. The results shown are the mean (±SEM) of 3 independent experiments. ***P < .01. (B) Colony assays for CFU-G/M, BFU-E, and CFU-E from Pf4-Cre/FAK-floxed and WT mice. No significant differences were found between the groups. The results represent the mean (± SEM) of 3 independent experiments.

Close modal

Increased mature megakaryocyte number and ploidy in Pf4-Cre/FAK-floxed mice

Next we determined whether the increase in CFU-MK number in Pf4-Cre/FAK-floxed mice leads to an increase in the number of mature bone marrow megakaryocytes. Sections of tibiae and femora from WT and Pf4-Cre/FAK-floxed mice were counterstained with hematoxylin and eosin and evaluated by light microscopy. The number of morphologically recognizable megakaryocytes was significantly increased in Pf4-Cre/FAK-floxed mice compared with WT (Figure 3A). To quantify megakaryocyte number, we counted the VWF-positive megakaryocytes per field of view (FOV; 200× magnification) in 3 mice from each group. The number of megakaryocytes was significantly increased in Pf4-Cre/Fak-floxed mice compared with WT (15.2 ± 0.83 per FOV in WT vs 28.9 ± 1.1 per FOV in Pf4-Cre/FAK-floxed; Figure 3B). In addition to megakaryocyte number, we also determined the effect of FAK ablation on megakaryocyte maturation. As a marker of megakaryocyte differentiation, we investigated the degree of megakaryocyte ploidy in vivo. We found a marked shift to higher ploidy in Pf4-Cre/FAK-floxed megakaryocytes compared with WT (Figure 3C). By quantifying the number of CD41+ megakaryocytes in each ploidy group, we determined that the geometric mean increased from 6.37 in WT to 10.03 in Pf4-Cre/FAK-floxed, and the percentage of megakaryocytes greater than 4N increased from 33% in WT to 52% in Pf4-Cre/FAK-floxed mice (Figure 3D). These results suggest that enhanced megakaryopoiesis might account for the increased platelet counts observed in Pf4-Cre/FAK-floxed mice.

Figure 3

Mature megakaryocyte number and ploidy are increased in Pf4-Cre/FAK-floxed mice. (A) Sections of mouse femora were stained with VWF and hematoxylin to identify megakaryocytes. The section shown is representative of preparations analyzed. (B) VWF-positive and morphologically recognizable megakaryocytes were counted per field of view. Numbers represent the mean (± SEM) of 10 counts taken from 3 mice in each group. ***P < .001 ≥. (C,D) In vivo ploidy analysis of CD41-positive bone marrow cells taken from WT and Pf4-Cre/FAK-floxed mice. CD41-positive ploidy peaks were gated on fluorescence on individual DNA peaks. The data shown are representative of 3 independent experiments.

Figure 3

Mature megakaryocyte number and ploidy are increased in Pf4-Cre/FAK-floxed mice. (A) Sections of mouse femora were stained with VWF and hematoxylin to identify megakaryocytes. The section shown is representative of preparations analyzed. (B) VWF-positive and morphologically recognizable megakaryocytes were counted per field of view. Numbers represent the mean (± SEM) of 10 counts taken from 3 mice in each group. ***P < .001 ≥. (C,D) In vivo ploidy analysis of CD41-positive bone marrow cells taken from WT and Pf4-Cre/FAK-floxed mice. CD41-positive ploidy peaks were gated on fluorescence on individual DNA peaks. The data shown are representative of 3 independent experiments.

Close modal

To determine whether the enhanced megakaryopoiesis might affect platelet recovery after induction of thrombocytopenia in Pf4-Cre/FAK-floxed mice, we generated thrombocytopenia using an antiplatelet CD41 antibody (Figure 4A). No difference was observed in the time for recovery to physiologic platelet counts (90 hours), but the extent of rebound thrombocytosis after recovery was significantly increased in the Pf4-Cre/FAK-floxed mice (170 hours; 1254 × 103/μL (± 36) in WT, compared with 1570 ×103/μL (± 63) in Fak−/− mice). Considering the greater megakaryocyte and platelet numbers in Pf4-Cre/FAK-floxed mice, we determined levels of Tpo in the plasma by ELISA. However, Tpo levels were not significantly different from those in WT mice (Figure 4B).

Figure 4

Platelet recovery following immune-induced thrombocytopenia in Pf4-Cre/FAK-floxed mice. (A) The data represent blood platelet levels measured at various time points following CD41 antibody administration. *P < .05. *P < .01. The numbers represent the mean platelet counts (± SEM) taken from 3 mice for each time point in each group. The data are representative of 2 independent experiments. (B) Levels of Tpo in plasma as determined by ELISA. Data represent mean (± SEM) from 5 mice in each group.

Figure 4

Platelet recovery following immune-induced thrombocytopenia in Pf4-Cre/FAK-floxed mice. (A) The data represent blood platelet levels measured at various time points following CD41 antibody administration. *P < .05. *P < .01. The numbers represent the mean platelet counts (± SEM) taken from 3 mice for each time point in each group. The data are representative of 2 independent experiments. (B) Levels of Tpo in plasma as determined by ELISA. Data represent mean (± SEM) from 5 mice in each group.

Close modal

Differences in Tpo-mediated activation of Lyn kinase, ERK, and AKT in FAK−/− megakaryocytes

Having demonstrated the involvement of FAK in megakaryocyte maturation, to elucidate the molecular mechanism responsible, we determined the effects of Fak ablation on signaling pathways previously found to be important in megakaryocyte differentiation. Mature bone marrow–derived megakaryocytes were Tpo starved for 16 hours before Tpo stimulation (50 ng/mL) for 5 minutes. In WT megakaryocytes, Tpo stimulation resulted in a 10-fold increase in Lyn kinase activity. However, Tpo did not stimulate Lyn kinase activity in Fak−/− megakaryocytes (Figure 5A). Western blot analyses clearly demonstrated a significant enhancement in the Tpo-mediated phosphorylation of both ERK1/2 and AKT in Fak−/− megakaryocytes compared with WT (Figure 5B,C). There was no difference in Tpo-mediated phosphorylation of JAK2, STAT3, or STAT5 (data not shown). These findings strongly suggest that FAK has a role in the negative regulation of Tpo-mediated signaling events important for megakaryocyte maturation downstream of JAK2 activation. Studies using the Tpo-dependent hematopoietic progenitor cell line UT7/Tpo indicate that Tpo is able to rapidly phosphorylate FAK in a dose-dependent manner in the absence of integrin engagement, suggesting a potential mechanism to alter the Tpo response (Figure 5D).

Figure 5

Increased Tpo-mediated signaling in FAK−/− megakaryocytes. (A) Lyn kinase assay of megakaryocytes derived from WT and Pf4-Cre/FAK-floxed mice in response to Tpo. Data represent autoradiography (top) and scintillation counts (bottom) of samples in triplicate. Data are representative of the mean (± SEM) of 2 independent experiments. (B,C) Western blot analyses of Tpo-mediated phosphorylation of ERK1/2 and AKT in WT and Fak−/− megakaryocytes. (D) Tpo-stimulated phosphorylation of FAK (Tyr925) in UT7/Tpo cells. The blotting results are representative of 3 independent experiments.

Figure 5

Increased Tpo-mediated signaling in FAK−/− megakaryocytes. (A) Lyn kinase assay of megakaryocytes derived from WT and Pf4-Cre/FAK-floxed mice in response to Tpo. Data represent autoradiography (top) and scintillation counts (bottom) of samples in triplicate. Data are representative of the mean (± SEM) of 2 independent experiments. (B,C) Western blot analyses of Tpo-mediated phosphorylation of ERK1/2 and AKT in WT and Fak−/− megakaryocytes. (D) Tpo-stimulated phosphorylation of FAK (Tyr925) in UT7/Tpo cells. The blotting results are representative of 3 independent experiments.

Close modal

Spreading of FAK−/− platelets

Platelet adhesion and aggregation are the 2 main mechanisms through which blood platelets ensure the preservation of cardiovascular-system integrity in the event of an injury. To demonstrate a role for FAK in the signaling events involved in the activation of platelets and general thrombus stability, the hemostatic abilities of WT and Pf4-Cre/FAK-floxed mice were tested in a tail rebleeding assay. Rebleeding times for Pf4-Cre/FAK-floxed mice were almost double those for WT (19 seconds ± 5.3 for the WT vs 37 ± 8.3 seconds for the Pf4-Cre/FAK-floxed mice; Figure 6A). Because FAK is known primarily for its involvement in cell adhesion and migration, we then investigated the ability of Fak−/− platelets to spread on immobilized fibrinogen. WT and Fak−/− platelets were incubated on fibrinogen-coated slides in the presence or absence of high concentrations of either ADP, collagen-related peptide (CRP), or the PAR4 agonist peptide (Figure 6B). Fak−/− platelets displayed significantly impaired spreading compared with WT platelets, both in the absence of added agonist and in the presence of ADP, collagen-related peptide (CRP), or PAR4 receptor–activating peptide. To determine whether impaired spreading in Fak−/− platelets was due to a loss of vinculin-rich focal adhesion structures,42  fibrinogen-bound platelets were stained for vinculin (Figure 6C) and analyzed by fluorescence microscopy. While Fak−/− platelets clearly displayed reduced spreading, their ability to form vinculin patches was unaltered, suggesting that the absence of FAK does not affect the formation of these particular adhesion structures. Fibrinogen-binding and clot-retraction assays were also performed on WT and Fak−/− platelets, and no significant difference was observed (data not shown).

Figure 6

FAK-null platelets support defective hemostasis and exhibit defective spreading on immobilized fibrinogen. (A) Tail rebleeding assays were performed on 10 mice in each group; the data are expressed as mean (horizontal bar), SEM (box), and data spread (vertical bar). (B) Platelet spreading was quantified by image analysis software and expressed as surface coverage; the numbers represent mean surface coverage (± SEM). **P < .01; ***P < .001. The data are representative of 3 independent experiments. (C) Platelets were allowed to spread on immobilized fibrinogen for 1 hour in the presence or absence of agonists before vinculin (red) and β3 integrin (green) staining. Scale bar equals 4 μm; white boxes indicate magnified areas.

Figure 6

FAK-null platelets support defective hemostasis and exhibit defective spreading on immobilized fibrinogen. (A) Tail rebleeding assays were performed on 10 mice in each group; the data are expressed as mean (horizontal bar), SEM (box), and data spread (vertical bar). (B) Platelet spreading was quantified by image analysis software and expressed as surface coverage; the numbers represent mean surface coverage (± SEM). **P < .01; ***P < .001. The data are representative of 3 independent experiments. (C) Platelets were allowed to spread on immobilized fibrinogen for 1 hour in the presence or absence of agonists before vinculin (red) and β3 integrin (green) staining. Scale bar equals 4 μm; white boxes indicate magnified areas.

Close modal

FAK regulates the activity of a number of diverse signaling molecules, including Rho- and Arf-family GTPases, PI3-K, ERK, and PLC-γ, both independently and through the formation of signaling crosstalk networks with growth factor receptors.14,15,43,45  Although we have a good understanding of the roles and signaling properties of FAK in vitro, our knowledge of its role in vivo is restricted by the fact that Fak knockout is lethal to mice at embryonic day 8.5.46  To overcome this problem, lineage-conditional Fak-null mice are used to study the roles of FAK in vivo.36  In this study we have explored the roles of FAK in megakaryopoiesis and platelet function by generating megakaryocyte lineage–specific Fak-null mice. Using these mice, we have established previously unrecognized roles for FAK in megakaryocyte maturation and platelet function.

Our measurements of megakaryocyte progenitors, megakaryocyte number in the bone marrow, and platelet counts indicate that FAK plays a significant role as a negative regulator of megakaryopoiesis. Controlling megakaryocyte progenitor proliferation and megakaryocyte differentiation requires an intricate network of growth factor–mediated signaling events, hematopoietic and nonhematopoietic cell interactions, and gene transcription.47  Our finding that FAK negatively regulates megakaryopoiesis, potentially via direct effects on the signals that emanate from the Tpo-stimulated c-Mpl receptor, adds an important and novel signaling mechanism to the several mechanisms already determined. It has been well documented that FAK contains an N-terminal FERM (protein 4.1, ezrin, radexin, moesin) domain,48  which is able to interact directly with growth factor receptors.49  As JAK2 has been shown to interact with Box1 of c-Mpl via its FERM domain,50  it is possible that FAK interacts with c-Mpl in a similar manner. We are currently investigating whether this is a mechanism for c-Mpl/FAK interactions. Given the previously described interactions between FAK and Src-family kinases (SFKs), it is important to consider recent work investigating the roles of Lyn and Fyn in megakaryopoiesis. Megakaryocytes express 6 of the 8 SFK members (Fyn, Fgr, Hck, Lyn, Src, and Yes); Fyn and Lyn are expressed at the highest levels and are activated in response to Tpo.51  Fyn expression increases dramatically during megakaryocyte differentiation. A previous study demonstrated the importance of Tyr112 in the cytoplasmic domain of c-Mpl for activation of Lyn and showed that inhibition of Lyn activity with PP2 increased ERK1/2 phosphorylation and kinase activity.52  More recently, a description of the megakaryocyte phenotype in Lyn−/− mice showed an increased number of megakaryocyte progenitors and mature megakaryocytes, increased megakaryocyte ploidy, and enhanced Tpo-mediated phosphorylation of ERK1/2 and AKT compared to WT.53  As the Pf4-Cre/FAK-floxed mice we describe are phenotypically almost identical to Lyn−/− mice, we investigated whether FAK was involved in Tpo-mediated Lyn kinase activity. We found that Tpo was unable to activate Lyn kinase in Fak−/− megakaryocytes, suggesting a critical role for FAK in Lyn activity in these cells and therefore providing a potential mechanism through which FAK regulates megakaryopoiesis. This result is somewhat surprising because, as previously discussed, SFKs are required for FAK activation following adhesion.8,10  However, our data suggest that FAK is also a prerequisite for Lyn activity following Tpo stimulation.

We have found that FAK does not play a major role in megakaryocyte adhesion, spreading, or migration. This, too, is surprising, because in other Fak-null models these cell behaviors represent the major phenotype. One possible explanation for the lack of a spreading and migration phenotype involves the FAK homologue PYK2. Previous work using Fak−/− fibroblasts demonstrated an increase in PYK2 expression,54  and targeting PYK2 to β1 integrin–containing focal adhesion sites using a chimeric PYK2-FAK-C-terminal protein rescues the Fak−/− phenotype.55  Using our model, we demonstrated no change in expression of PYK2 in Pf4-Cre/FAK-floxed mice. However, PYK2 phosphorylation in response to fibrinogen and MnCl2 is increased in Fak−/− megakaryocytes compared with WT controls. It is possible that increased PYK2 activity is able to compensate in the absence of FAK to maintain normal megakaryocyte adhesion and spreading. This theory is supported by previous findings that suggest PYK2 is able to localize to focal adhesion sites in megakaryocytic cells and is activated following integrin engagement.28  We have shown no increase in PYK2 activity in response to various agonists in FAK-null platelets. The more pronounced difference in FAK-null platelet spreading compared with megakaryocyte spreading may be due to the lack of PYK2 compensation in platelets.

The potential roles of FAK in platelet function have been previously described.30,,,34  Those earlier studies and our research described here together demonstrate that FAK is rapidly phosphorylated following a combination of integrin and agonist signals. However, before this study, the lack of a viable FAK-null mouse has prevented confirmation of these findings in vivo. Although our studies using Fak−/− platelets are just beginning, it appears from the observed defects in platelet spreading and tail rebleeding times that FAK may be of considerable importance for platelet αIIbβ3 integrin outside-in signaling and thrombus stability. Our results suggest that one of the major roles of FAK in platelets is the reorganization of the actin cytoskeleton to initiate spreading rather than to recruit proteins such as vinculin to nascent adhesion structures. Additional studies will be required, and are now possible, to more fully understand the role of platelet FAK in hemostasis.

In this study, we further demonstrated the great potential of the Pf4-Cre mouse in determining the roles of specific proteins in megakaryocytes and platelets. The ability to ablate a specific floxed gene from these cells now allows in vivo characterization of genes of interest with functions that had been previously undescribed because of their vital role or roles in development of other cell lineages. Using these mice, we have been able to demonstrate novel roles for FAK in mediating megakaryocyte differentiation in vivo, and Tpo-mediated intracellular signaling in vitro. In addition, we have provided the first insights into the phenotype of Fak−/− platelets. Further studies with these mice may reveal potential future therapeutic targets for the control of platelet numbers and function.

An Inside Blood analysis of this article appears at the front of this issue.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 USC section 1734.

We thank Mark Ginsberg (University of California San Diego) for experimental advice and insightful discussions. We also thank Radek Skoda (Basel University Hospital, Switzerland) and Hillary Beggs (University of California San Francisco) for kindly providing the Pf4-Cre and FAK-floxed mice, respectively.

Research was supported by National Institutes of Health grants R01DK49855 and P01 HL078784-04 (I.S.H, N.E.F, K.S., and K.K.), and HL78784 and HL57900 (N.P. and S.J.S).

National Institutes of Health

Contribution: All authors substantially contributed to the content of the paper and have agreed to the submission in its current format. I.S.H. designed and performed research, analyzed data, and wrote the manuscript; N.E.F. and K.S. designed and performed experiments and analyzed data; N.P. designed and performed experiments, analyzed data, and wrote the manuscript; S.J.S. designed experiments and wrote the manuscript; and K.K. designed experiments, interpreted data, and wrote the manuscript.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Correspondence: Kenneth Kaushansky, Department of Medicine, University of California San Diego, 9500 Gilman Dr, La Jolla, CA 92093; e-mail: kkaushansky@ucsd.edu.

1
Fox
 
GL
Rebay
 
I
Hynes
 
RO
Expression of DFak56, a Drosophila homolog of vertebrate focal adhesion kinase, supports a role in cell migration in vivo.
Proc Natl Acad Sci U S A
1999
96
14978
14983
2
Hanks
 
SK
Calalb
 
MB
Harper
 
MC
Patel
 
SK
Focal adhesion protein-tyrosine kinase phosphorylated in response to cell attachment to fibronectin.
Proc Natl Acad Sci U S A
1992
89
8487
8491
3
Henry
 
CA
Crawford
 
BD
Yan
 
YL
et al
Roles for zebrafish focal adhesion kinase in notochord and somite morphogenesis.
Dev Biol
2001
240
474
487
4
Schaller
 
MD
Borgman
 
CA
Cobb
 
BS
et al
pp125FAK a structurally distinctive protein-tyrosine kinase associated with focal adhesions.
Proc Natl Acad Sci U S A
1992
89
5192
5196
5
Guan
 
JL
Shalloway
 
D
Regulation of focal adhesion-associated protein tyrosine kinase by both cellular adhesion and oncogenic transformation.
Nature
1992
358
690
692
6
Parsons
 
JT
Focal adhesion kinase: the first ten years.
J Cell Sci
2003
116
1409
1416
7
Sieg
 
DJ
Hauck
 
CR
Ilic
 
D
et al
FAK integrates growth-factor and integrin signals to promote cell migration.
Nat Cell Biol
2000
2
249
256
8
Schaller
 
MD
Hildebrand
 
JD
Shannon
 
JD
et al
Autophosphorylation of the focal adhesion kinase, pp125FAK, directs SH2-dependent binding of pp60src.
Mol Cell Biol
1994
14
1680
1688
9
Xing
 
Z
Chen
 
HC
Nowlen
 
JK
et al
Direct interaction of v-Src with the focal adhesion kinase mediated by the Src SH2 domain.
Mol Cell Biol
1994
5
413
421
10
Gabarra-Niecko
 
V
Keely
 
PJ
Schaller
 
MD
Characterization of an activated mutant of focal adhesion kinase: ‘SuperFAK’.
Biochem J
2002
365
591
603
11
Lim
 
Y
Han
 
I
Jeon
 
J
et al
Phosphorylation of focal adhesion kinase at tyrosine 861 is crucial for Ras transformation of fibroblasts.
J Biol Chem
2004
279
29060
29065
12
Schlaepfer
 
DD
Hanks
 
SK
Hunter
 
T
van der Geer
 
P
Integrin-mediated signal transduction linked to Ras pathway by GRB2 binding to focal adhesion kinase.
Nature
1994
372
786
791
13
Carragher
 
NO
Levkau
 
B
Ross
 
R
Raines
 
EW
Degraded collagen fragments promote rapid disassembly of smooth muscle focal adhesions that correlates with cleavage of pp125(FAK), paxillin, and talin.
J Cell Biol
1999
147
619
630
14
Reiske
 
HR
Kao
 
SC
Cary
 
LA
et al
Requirement of phosphatidylinositol 3-kinase in focal adhesion kinase-promoted cell migration.
J Biol Chem
1999
274
12361
12366
15
Zhang
 
X
Chattopadhyay
 
A
Ji
 
QS
et al
Focal adhesion kinase promotes phospholipase C-gamma1 activity.
Proc Natl Acad Sci U S A
1999
96
9021
9026
16
Mitra
 
SK
Hanson
 
DA
Schlaepfer
 
DD
Focal adhesion kinase: in command and control of cell motility.
Nat Rev Mol Cell Biol
2005
6
56
68
17
Ilić
 
D
Furuta
 
Y
Kanazawa
 
S
et al
Reduced cell motility and enhanced focal adhesion contact formation in cells from FAK-deficient mice.
Nature
1995
377
539
544
18
Owen
 
JD
Ruest
 
PJ
Fry
 
DW
Hanks
 
SK
Induced focal adhesion kinase (FAK) expression in FAK-null cells enhances cell spreading and migration requiring both auto- and activation loop phosphorylation sites and inhibits adhesion-dependent tyrosine phosphorylation of Pyk2.
Mol Cell Biol
1999
19
4806
4818
19
Kaushansky
 
K
Lok
 
S
Holly
 
RD
et al
Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin.
Nature
1994
369
568
571
20
Ku
 
H
Yonemura
 
Y
Kaushansky
 
K
Ogawa
 
M
Thrombopoietin, the ligand for the Mpl receptor, synergizes with steel factor and other early acting cytokines in supporting proliferation of primitive hematopoietic progenitors of mice.
Blood
1996
87
4544
4551
21
Avecilla
 
ST
Hattori
 
K
Heissig
 
B
et al
Chemokine-mediated interaction of hematopoietic progenitors with the bone marrow vascular niche is required for thrombopoiesis.
Nat Med
2004
10
64
71
22
Slayton
 
WB
Wainman
 
DA
Li
 
XM
et al
Developmental differences in megakaryocyte maturation are determined by the microenvironment.
Stem Cells
2005
23
1400
1408
23
Fox
 
NE
Kaushansky
 
K
Engagement of integrin alpha4beta1 enhances thrombopoietin-induced megakaryopoiesis.
Exp Hematol
2005
33
94
99
24
Larson
 
MK
Watson
 
SP
Regulation of proplatelet formation and platelet release by integrin alpha IIb beta3.
Blood
2006
108
1509
1514
25
Zweegman
 
S
Veenhof
 
MA
Huijgens
 
PC
Schuurhuis
 
GJ
Drager
 
AM
Regulation of megakaryocytopoiesis in an in vitro stroma model: preferential adhesion of megakaryocytic progenitors and subsequent inhibition of maturation.
Exp Hematol
2000
28
401
410
26
Avraham
 
S
London
 
R
Fu
 
Y
et al
Identification and characterization of a novel related adhesion focal tyrosine kinase (RAFTK) from megakaryocytes and brain.
J Biol Chem
1995
270
27742
27751
27
Hiregowdara
 
D
Avraham
 
H
Fu
 
Y
London
 
R
Avraham
 
S
Tyrosine phosphorylation of the related adhesion focal tyrosine kinase in megakaryocytes upon stem cell factor and phorbol myristate acetate stimulation and its association with paxillin.
J Biol Chem
1997
272
10804
10810
28
Li
 
J
Avraham
 
H
Rogers
 
RA
Raja
 
S
Avraham
 
S
Characterization of RAFTK, a novel focal adhesion kinase, and its integrin-dependent phosphorylation and activation in megakaryocytes.
Blood
1996
88
417
428
29
Avraham
 
H
Park
 
SY
Schinkmann
 
K
Avraham
 
S
RAFTK/Pyk2-mediated cellular signalling.
Cell Signal
2000
12
123
133
30
Huang
 
MM
Lipfert
 
L
Cunningham
 
M
et al
Adhesive ligand binding to integrin alpha IIb beta 3 stimulates tyrosine phosphorylation of novel protein substrates before phosphorylation of pp125FAK.
J Cell Biol
1993
122
473
483
31
Lipfert
 
L
Haimovich
 
B
Schaller
 
MD
et al
Integrin-dependent phosphorylation and activation of the protein tyrosine kinase pp125FAK in platelets.
J Cell Biol
1992
119
905
912
32
Shattil
 
SJ
Haimovich
 
B
Cunningham
 
M
et al
Tyrosine phosphorylation of pp125FAK in platelets requires coordinated signaling through integrin and agonist receptors.
J Biol Chem
1994
269
14738
14745
33
Haimovich
 
B
Kaneshiki
 
N
Ji
 
P
Protein kinase C regulates tyrosine phosphorylation of pp125FAK in platelets adherent to fibrinogen.
Blood
1996
87
152
161
34
Haimovich
 
B
Lipfert
 
L
Brugge
 
JS
Shattil
 
SJ
Tyrosine phosphorylation and cytoskeletal reorganization in platelets are triggered by interaction of integrin receptors with their immobilized ligands.
J Biol Chem
1993
268
15868
15877
35
Izaguirre
 
G
Aguirre
 
L
Hu
 
YP
et al
The cytoskeletal/non-muscle isoform of alpha-actinin is phosphorylated on its actin-binding domain by the focal adhesion kinase.
J Biol Chem
2001
276
28676
28685
36
Beggs
 
HE
Schahin-Reed
 
D
Zang
 
K
et al
FAK deficiency in cells contributing to the basal lamina results in cortical abnormalities resembling congenital muscular dystrophies.
Neuron
2003
40
501
514
37
Tiedt
 
R
Schomber
 
T
Hao-Shen
 
H
Skoda
 
RC
Pf4-Cre transgenic mice allow the generation of lineage-restricted gene knockouts for studying megakaryocyte and platelet function in vivo.
Blood
2007
109
1503
1506
38
Geddis
 
AE
Kaushansky
 
K
Megakaryocytes express functional Aurora-B kinase in endomitosis.
Blood
2004
104
1017
1024
39
Dhanjal
 
TS
Pendaries
 
C
Ross
 
EA
et al
A novel role for PECAM-1 in megakaryocytokinesis and recovery of platelet counts in thrombocytopenic mice.
Blood
2007
109
4237
4244
40
Arias-Salgado
 
EG
Haj
 
F
Dubois
 
C
et al
PTP-1B is an essential positive regulator of platelet integrin signaling.
J Cell Biol
2005
170
837
845
41
Yang
 
J
Wu
 
J
Kowalska
 
MA
et al
Loss of signaling through the G protein, Gz, results in abnormal platelet activation and altered responses to psychoactive drugs.
Proc Natl Acad Sci U S A
2000
97
9984
9989
42
Leng
 
L
Kashiwagi
 
H
Ren
 
XD
Shattil
 
SJ
RhoA and the function of platelet integrin alphaIIbbeta3.
Blood
1998
91
4206
4215
43
Akagi
 
T
Murata
 
K
Shishido
 
T
Hanafusa
 
H
v-Crk activates the phosphoinositide 3-kinase/AKT pathway by utilizing focal adhesion kinase and H-Ras.
Mol Cell Biol
2002
22
7015
7023
44
Gabarra-Niecko
 
V
Schaller
 
MD
Dunty
 
JM
FAK regulates biological processes important for the pathogenesis of cancer.
Cancer Metastasis Rev
2003
22
359
374
45
Liu
 
G
Guibao
 
CD
Zheng
 
J
Structural insight into the mechanisms of targeting and signaling of focal adhesion kinase.
Mol Cell Biol
2002
22
2751
2760
46
Furuta
 
Y
Ilic
 
D
Kanazawa
 
S
et al
Mesodermal defect in late phase of gastrulation by a targeted mutation of focal adhesion kinase, FAK.
Oncogene
1995
11
1989
1995
47
Kaushansky
 
K
The molecular mechanisms that control thrombopoiesis.
J Clin Invest
2005
115
3339
3347
48
Dunty
 
JM
Gabarra-Niecko
 
V
King
 
ML
et al
FERM domain interaction promotes FAK signaling.
Mol Cell Biol
2004
24
5353
5368
49
Chen
 
SY
Chen
 
HC
Direct interaction of focal adhesion kinase (FAK) with Met is required for FAK to promote hepatocyte growth factor-induced cell invasion.
Mol Cell Biol
2006
26
5155
5167
50
Drachman
 
JG
Kaushansky
 
K
Dissecting the thrombopoietin receptor: functional elements of the Mpl cytoplasmic domain.
Proc Natl Acad Sci U S A
1997
94
2350
2355
51
Lannutti
 
BJ
Shim
 
MH
Blake
 
N
Reems
 
JA
Drachman
 
JG
Identification and activation of Src family kinases in primary megakaryocytes.
Exp Hematol
2003
31
1268
1274
52
Lannutti
 
BJ
Drachman
 
JG
Lyn tyrosine kinase regulates thrombopoietin-induced proliferation of hematopoietic cell lines and primary megakaryocytic progenitors.
Blood
2004
103
3736
3743
53
Lannutti
 
BJ
Minear
 
J
Blake
 
N
Drachman
 
JG
Increased megakaryocytopoiesis in Lyn-deficient mice.
Oncogene
2006
25
3316
3324
54
Sieg
 
DJ
Ilic
 
D
Jones
 
KC
et al
Pyk2 and Src-family protein-tyrosine kinases compensate for the loss of FAK in fibronectin-stimulated signaling events but Pyk2 does not fully function to enhance FAK- cell migration.
EMBO J
1998
17
5933
5947
55
Klingbeil
 
CK
Hauck
 
CR
Hsia
 
DA
et al
Targeting Pyk2 to beta 1-integrin-containing focal contacts rescues fibronectin-stimulated signaling and haptotactic motility defects of focal adhesion kinase-null cells.
J Cell Biol
2001
152
97
110
Sign in via your Institution